2.Globin gene induction therapy for β-thalassemia.
Journal of Experimental Hematology 2014;22(1):237-240
Globin gene induction therapy is a new treatment under study for β-thalassemia. This review summarizes the research progress on the mechanisms of globin gene induction therapy for β-thalassemia and current γ-globin gene induction medicines.
Animals
;
Genetic Therapy
;
Globins
;
genetics
;
Humans
;
beta-Thalassemia
;
therapy
3.Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload.
Samin ALAVI ; Elham SADEGHI ; Azin ASHENAGAR
Blood Research 2014;49(1):72-73
No abstract available.
beta-Thalassemia*
;
Chelation Therapy*
;
Humans
;
Iron Overload*
;
Iron*
4.Research Progress on Gene Therapy for β-thalassemia---Review.
Wei-Cong HONG ; Jian-Pei FANG ; Lyu-Hong XU
Journal of Experimental Hematology 2021;29(5):1676-1679
β-thalassemia is a monogenetic inherited hemolytic anemia, which results in a series of pathophysiological changes due to partial or complete inhibition of the synthesis of β-globin chain. The curative therapy for this disease is to reconstitute hematopoiesis, and transplantation with genetically modified autologous hematopoietic stem cells can avoid the major difficulties of traditional allogeneic hematopoietic stem cell transplantation,such as HLA matching and immune rejection. β-thalassemia gene therapy strategies mainly include gene integration and genome editing. The former relies on the development of lentiviral vectors and adds a fully functional HBB gene to the chromosome; the latter rapidly develops with the research of specific nuclease which can repair the HBB gene in situ. In this review, the latest progress of the two strategies in gene therapy of β-thalassemia is summarized.
Gene Editing
;
Genetic Therapy
;
Genetic Vectors
;
Humans
;
beta-Globins/genetics*
;
beta-Thalassemia/therapy*
5.Comparision of Allogeneic Hematopoietic Stem Cell Transplantation between Children with Thalassemia of Different Ages.
Dong-Liang KANG ; Yong-Hong TAN ; Ya-Mei CHEN ; Jing-Yuan LU ; Jie SHI ; Xiu-Zhen YAN ; Quan-Yi LU
Journal of Experimental Hematology 2022;30(2):539-542
OBJECTIVE:
To investigate the difference of therapeutic effects on children with thalassemia at different age after hematopoietic stem cell transplantation.
METHODS:
The clinical data of children with thalassemia treated in our hospital were retrospectively analyzed. The children were divided into 2-5 years old group and 6-12 years old group. The success rate of implantation, transplant-related mortality, GVHD incidence, and other transplant-related complications, as well as thalassemia-free survival (TFS) were compared between the two groups.
RESULTS:
The incidence of GVHD, hemorrhagic cystitis and severe oral mucositis after transplantation in the 2-5 years old group were significantly lower than those in the 6-12 years old group, while there was no statistically significant difference in the TFS between the two groups.
CONCLUSION
Children in the low age (2-5 years old) group show fewer complications and higher quality of life after transplantation, therefore, stem cell transplantation at 2-5 years old is more conducive to rehabilitation of the children with thalassemia.
Child
;
Child, Preschool
;
Graft vs Host Disease/complications*
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Quality of Life
;
Retrospective Studies
;
Thalassemia/therapy*
;
beta-Thalassemia/therapy*
6.Relationship between liver iron concentration determined by R2-MRI, serum ferritin, and liver enzymes in patients with thalassemia intermedia.
Hayder AL-MOMEN ; Shaymaa Kadhim JASIM ; Qays Ahmed HASSAN ; Hayder Hussein ALI
Blood Research 2018;53(4):314-319
BACKGROUND: Iron overload is a risk factor affecting all patients with thalassemia intermedia (TI). We aimed to determine whether there is a relationship of serum ferritin (SF) and alanine aminotransferase (ALT) with liver iron concentration (LIC) determined by R2 magnetic resonance imaging (R2-MRI), to estimate the most relevant degree of iron overload and best time to chelate in patients with TI. METHODS: In this cross-sectional study, 119 patients with TI (mean age years) were randomly selected and compared with 120 patients who had a diagnosis of thalassemia major (TM). Correlations of LIC, as determined by R2-MRI, with SF and ALT levels, were assessed in all participants. A P-value < 0.05 was considered statistically significant. RESULTS: SF and LIC levels were lower in patients with TI than in those with TM; only ferritin values were significant. We found a statistically significant relationship between SF and LIC, with cut-off estimates of SF in patients with TI who had splenectomy and those who entered puberty spontaneously (916 and 940 ng/mL, respectively) with LIC >5 mg Fe/g dry weight (P < 0.0001). A significant relationship was also found for patients with TI who had elevated ALT level (63.5 U/L), of 3.15 times the upper normal laboratory limit, using a cut-off for LIC ≥5 mg Fe/g dry weight. CONCLUSION: We determined the cut-off values for ALT and SF indicating the best time to start iron chelation therapy in patients with TI, and found significant correlations among iron overload, SF, and ALT.
Adolescent
;
Alanine Transaminase
;
beta-Thalassemia*
;
Chelation Therapy
;
Cross-Sectional Studies
;
Diagnosis
;
Ferritins*
;
Humans
;
Iron Overload
;
Iron*
;
Liver*
;
Magnetic Resonance Imaging
;
Puberty
;
Risk Factors
;
Splenectomy
;
Thalassemia*
7.Advances in Pathogenesis and Related Clinical Research of Thromboembolism in Patients with Thalassemia after Splenectomy.
Na SUN ; Peng CHENG ; Dong-Hong DENG
Journal of Experimental Hematology 2016;24(3):949-953
Thalassemia is the most common human hereditary hemolytic anemia. Due to splenomegaly and hypersp-lenism, splenectomy can be used as a means of treatment for thalassemia. Various complications following splenectomy, however, especially thromboembolic complications are remarkable. This review summarizes the incidence, clinical manifestations and development time of thromboembolism. The pathogenesis of thromboembolism after splenectomy in thalassemia, such as abnormal platelet number and function, changes in red cell membrane, endothelial cell damage, dysfunction of other procoagulant and anticoagulant factors, and local factors associated with splenectomy are elaborated and the trategies to prevent and treat the thromboembolic events in thalassemia after splenectomy, including the attention to risk factors associated with splenectomy, a reassessment of splenectomy, regular blood transfusion to reduce the ratio of abnormal red blood cells, treatment with anticoagulant and antiplatelet drugs, application of hydroxyurea and stem cell transplantation are discussed.
Anticoagulants
;
therapeutic use
;
Blood Transfusion
;
Humans
;
Risk Factors
;
Splenectomy
;
Thalassemia
;
pathology
;
Thromboembolism
;
pathology
;
prevention & control
;
therapy
8.Role of chimerism monitoring and donor lymphocyte infusion in eliminating the risk of graft rejection following HSCT in thalassemia patients-review.
Journal of Experimental Hematology 2013;21(5):1356-1360
One of the major obstacle for hematopoietic stem cell transplantation (HSCT) to treat patients with beta-thalassemia is graft rejection (GR). The proportion of donor-derived cells continually declined in mixed chimerism (MC), finally leading to graft failure. Monitoring chimerism after transplant consecutively can early find unstable mixed chimerism and rejection, which provide the basis for donor lymphocyte infusion (DLI); for imminent risk of graft rejection, escalating doses of DLI is a feasible method for converting unstable MC towards stable MC or full donor chimerism. This review focuses on advancement of chimerism monitoring and DLI after HSCT for patients with β-thalassemia major.
Graft Rejection
;
etiology
;
Humans
;
Lymphocyte Transfusion
;
Thalassemia
;
therapy
;
Tissue Donors
;
Transplantation Chimera
9.Expression, functional mechanism and therapy application of long noncoding RNA in β-thalassemia.
Yali PAN ; Liangpu XU ; Hailong HUANG
Journal of Central South University(Medical Sciences) 2022;47(2):252-257
β-thalassemia (β-thal) is one of the most common genetic diseases in the world, its pathogenesis is extremely complex and there is no effective treatment at present. The birth of children with moderate and severe β-thal brings economic pressure to families, social medical and health services. Long noncoding RNA (lncRNA) is a type of noncoding protein transcripts with a length greater than 200 nucleotides, which is involved in a variety of biological processes, such as cell proliferation, differentiation and chromosome variation and plays an important role in the epigenetic and post-transcriptional regulation of genes. It has potential value in the diagnosis, prevention and treatment of β-thal. LncRNA possesses the characteristics such as tissue specificity, cell specificity, developmental stage specificity, space-time specificity and disease specificity, and its complex interaction network has become a challenge to translate research results into clinical practice. Taking lncRNA as an entry point, in-depth understanding of the function of lncRNA in β-thal and explanation of its related regulatory mechanisms will provide theoretical basis for targeting treatment of β-thal, which can improve the diagnosis and treatment of β-thal.
Cell Differentiation
;
Child
;
Gene Expression Regulation
;
Humans
;
RNA, Long Noncoding/genetics*
;
beta-Thalassemia/therapy*
10.γ-Globin Inductive Therapy of β-thalassemia and Its Relationship with MicroRNA.
Yao-Yao LI ; Jian GU ; Duo-Nan YU
Journal of Experimental Hematology 2016;24(2):627-631
β-thalassemia is a chronic hemolytic anemia characterized by the reduction or absence of synthesis of β-globin chains because of the β-globin gene mutations. β-thalassemia belongs to the inherited hemoglobin disease, and occurs in some provinces of China, such as in Guangdong, Guangxi, Fujian, its prevalence is about 2%. The treatment of this disease include transfusion, iron chelating agent, hematopoietic stem cell transplantation, splenectomy, induced expression of Fetal Hemoglobin (HbF) and gene therapies. However, the mortality rate of this disease is still higher, thus some new treatments are urgently needed. In recent years, the study was mainly concentrated in 2 aspects: the normal β-globin gene transfer and endogenous γ-globin re-activation. Some studies showed that the expression of miRNAs was dysregulated in β-thalassemia. Some miRNAs could regulate γ-globin at posttranscriptional level, thus, the clarification of relationship between miRNAs and β-thalassemia is expected to provide experimental bases to β-thalassemia therapy. In this review, the induced therapy of γ-globin for β-thalassemia and its relationship with the miRNA are summarized.
China
;
Fetal Hemoglobin
;
metabolism
;
Genetic Therapy
;
Humans
;
MicroRNAs
;
metabolism
;
beta-Globins
;
genetics
;
beta-Thalassemia
;
therapy
;
gamma-Globins
;
therapeutic use